Print

Cancer Research Consortium of West Michigan

Pediatric Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

Provided drugs are underlined

For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079

Brain/CNS

Cancer Type: Medulloblastoma/PNET
Research Base: COG
Protocol: COG ACNS0332

COG-ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients. Patients age > 3 and < 22 years at the time of diagnosis.

Clinical Summary:

Cancer Type: Newly Diagnosed Ependymoma
Research Base: COG
Protocol: COG ACNS0831

COG ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years. Patients > 12 months and < 21 years of age.

Clinical Summary:

Cancer Type: CNS Germ Cell Tumors
Research Base: COG
Protocol: COG ACNS1123

COG ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT). Patients must be ≥ 3 years and ≤ 21 years of age. TEMPORARY CLOSURE

Clinical Summary:

Cancer Type: Neuroblastoma-Biology
Research Base: COG
Protocol: COG ANBL00B1

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

Clinical Summary:

Cancer Control

Cancer Type: Evidence-Based Supportive Care
Research Base: COG
Protocol: COG ACCL15N1CD
 

COG ACCL15N1CD: Use of Evidence-Based Supportive Care Clinical Practice Guidelines in Pediatric Oncology

Clinical Summary:

Cancer Type: Pediatric ALL
Research Base: COG
Protocol: COG ACCL1033

COG ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL - Partial Closure: stratum Hispanic < 12 years old. Diagnosis of ALL at ≥ 1 year and ≤ 21 years of age, in first remission. 

Clinical Summary:

Cancer Type: Multi-site Cancer Control
Research Base: COG
Protocol: COG ALTE03N1

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

Clinical Summary:

Cancer Type: Multi-Site Cancer Control
Research Base: COG
Protocol: COG ALTE07C1

COG ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer

Clinical Summary:

Gastrointestinal

Cancer Type: Hepatoblastoma
Research Base: COG
Protocol: COG AHEP0731

COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment. Patients must be < 21 years at the time of diagnosis.

Clinical Summary:

Genitourinary

Cancer Type: Renal-Biology
Research Base: COG
Protocol: COG AREN03B2

COG AREN03B2: Renal Tumors Classification, Biology, and Banking Study. Patients must be < 30 years old at the time of diagnosis.

Clinical Summary:

Leukemia

Cancer Type: AML
Research Base: COG
Protocol: COG AAML1531

COG-AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Children with Down syndrome > 90 days and < 4 years of age at diagnosis of AML or Myelodysplastic Syndrome (MDS) 

Clinical Summary:

Cancer Type: B-ALL Relapse
Research Base: COG
Protocol: COG AALL1331

COG AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Age - Patients ≥1 year and < 31 years of age at the time of relapse will be eligible.

Clinical Summary:

Cancer Type: Acute Promyelocytic Leukemia (APL)
Research Base: COG
Protocol: COG AAML1331
COG AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic
Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid
 
Patient must be ≥ 12 months and < 22 years of age at first diagnosis of APL

Clinical Summary:

Cancer Type: T-ALL & T-LLy
Research Base: COG
Protocol: COG AALL1231

COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). All patients must be > 1 and < 31 years of age.

Clinical Summary:

Cancer Type: Leukemia ALL
Research Base: COG
Protocol: COG AALL05B1

COG-AALL05B1: Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens. Age <31 years of age at the time of initial diagnosis of ALL.

Clinical Summary:

Cancer Type: ALL-Ancillary
Research Base: COG
Protocol: COG AALL08B1

COG AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL).  < 31 years of age at diagnosis of acute leukemia. 

Clinical Summary:

Cancer Type: ALL
Research Base: COG
Protocol: COG AALL0932

COG-AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy). Patients must be > 365 days and < 10 years of age

Clinical Summary:

Cancer Type: High Risk B-ALL
Research Base: COG
Protocol: COG AALL1131

COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Patients must be > 365 days and < 31 years of age



 

Clinical Summary:

Cancer Type: Leukemia-AML
Research Base: COG
Protocol: COG AAML08B1

COG AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS). Patient is < 90 days of age at diagnosis of TMD

Clinical Summary:

Cancer Type: de novo AML
Research Base: COG
Protocol: COG AAML1031

COG AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD. Patients must be less than 30 years of age.
 

Clinical Summary:

Cancer Type: Pediatric ALL
Research Base: COG
Protocol: COG ACCL1033

COG ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL - Partial Closure: stratum Hispanic < 12 years old. Diagnosis of ALL at ≥ 1 year and ≤ 21 years of age, in first remission. 

Clinical Summary:

Lymphoma

Cancer Type: T-ALL & T-LLy
Research Base: COG
Protocol: COG AALL1231

COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). All patients must be > 1 and < 31 years of age.

Clinical Summary:

Cancer Type: Hodgkin Lymphoma (cHL)
Research Base: COG
Protocol: COG AHOD1331

COG-AHOD1331: A Randomized Phase III Study of Brentuximab vedotin (IND #117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Ages > 2 - < 19 years

Clinical Summary:

Cancer Type: ALCL
Research Base: COG
Protocol: COG ANHL12P1

COG ANHL12P1: A Randomized Phase 2 study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117. TEMPORARY CLOSURE

Patient must be < 22 years of age.

Clinical Summary:

Cancer Type: Misc-Lymphoma
Research Base: COG
Protocol: COG ALTE11C1

COG ALTE11C1: Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma.

Patients must be < 30 years of age.

Clinical Summary:

Cancer Type: Lymphoma-NHL Registry
Research Base: COG
Protocol: COG ANHL04B1

COG ANHL04B1: Rare and Cutaneous Non-Hodgkin Lymphoma Registry. Age 0-20.99 years.

Clinical Summary:

Multisite

Cancer Type: All patients
Research Base: COG
Protocol: COG APEC14B1

Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit.

Clinical Summary:

Cancer Type: Cancer Registry
Research Base: COG
Protocol: COG ACCRN07
 

COG ACCRN07: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)

Clinical Summary:

Cancer Type: Multi-site Cancer Control
Research Base: COG
Protocol: COG ALTE03N1

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

Clinical Summary:

Cancer Type: Multisite Long Term Follow-up
Research Base: COG
Protocol: COG ALTE05N1

COG ALTE05N1: Umbrella Long-term Follow-up Protocol. Only available to patients already enrolled on a COG intervention protocol.

Clinical Summary:

Cancer Type: Multi-Site Cancer Control
Research Base: COG
Protocol: COG ALTE07C1

COG ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer

Clinical Summary:

Neuroblastoma

Cancer Type: Refractory, Relapsed or Progressive Neuroblastoma
Research Base: COG
Protocol: COG ANBL1221

COG ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma. Patients of all ages. TEMPORARY CLOSURE

Clinical Summary:

Cancer Type: NBL
Research Base: COG
Protocol: COG ANBL1232

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

Clinical Summary:

Cancer Type: Neuroblastoma-Biology
Research Base: COG
Protocol: COG ANBL00B1

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

Clinical Summary:

Sarcoma

Cancer Type: Ewing Sarcoma
Research Base: COG
Protocol: COG AEWS07B1

COG AEWS07B1: A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens

Clinical Summary:

Cancer Type: Ewing Sarcoma
Research Base: COG
Protocol: COG AEWS1031

COG-AEWS1031: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma. Age 0-50. TEMPORARY CLOSURE

Clinical Summary:

Cancer Type: Soft Tissue Sarcomas
Research Base: COG
Protocol: COG ARST1321

COG ARST1321: Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) 

Patients must be ≥ 2 years at the time of the biopsy that established the diagnosis of NRSTS will be eligible

Clinical Summary:

Cancer Type: Ewing Sarcoma
Research Base: COG
Protocol: COG AEWS1221

COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma 

Patients ≤ 50 years of age at enrollment will be eligible for this study.

Clinical Summary:

Cancer Type: Osteosarcoma-Biology
Research Base: COG
Protocol: COG AOST06B1

COG AOST06B1: A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens. There are no age limitations on this study.

Clinical Summary:

Cancer Type: Osteosarcoma
Research Base: COG
Protocol: COG AOST1321

COG-AOST1321: Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma - Partial Closure to Accrual: Stratum 1 (Stage 1 of Cohort 1)

Patients must be equal to or greater than 11 years of age but less than 50 years of age at the time of enrollment.

Clinical Summary:

Cancer Type: IR Rhabdomyosarcoma
Research Base: COG
Protocol: COG ARST1431

COG-ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) TEMPORARY CLOSURE

Feasibility Phase: Patients must be < 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≤ 40 years of age at the time of enrollment. 

Clinical Summary:

Cancer Type: Osteosarcoma
Research Base: COG
Protocol: COG AOST1421

COG AOST1421: A Phase 2 Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma  - Temporary Closure

Patients must be less than 30 years of age at enrollment.

Clinical Summary: